<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        140-334-11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VEXAL XR 37.5 MG EXTENDED RELEASE CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENLAFAXINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        37.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        30.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMATHEN INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMATHEN INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vexal XR contains the active substance venlafaxine.</p><p>Vexal XR is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders. It is thought that people who are depressed and/or anxious have lower levels of serotonin and norepinephrine in the brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of serotonin and norepinephrine in the brain.</p><p>Vexal XR is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: generalised anxiety disorder, social anxiety disorder (fear or avoidance of social situations) and panic disorder (panic attacks). Treating depression or anxiety disorders properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and more difficult to treat.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>Vexal </strong><strong>XR</strong></p><ul><li>If you are allergic to venlafaxine or any of the other ingredients of this medicine (listed in section 6).</li><li>If you are also taking, or have taken within the last 14 days, any medicines known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson&rsquo;s disease. Taking an irreversible MAOI together with Vexal<strong> </strong>XR, can cause serious or even life-threatening side effects. Also, you must wait at least 7 days after you stop taking Vexal<strong> </strong>XR before you take any MAOI (see also the section entitled &ldquo;Other medicines and Vexal<strong> </strong>XR&rdquo; and the information in that section about &lsquo;Serotonin Syndrome&rsquo;).</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Vexal<strong> </strong>XR:</p><ul><li>If you use other medicines that taken together with Vexal XR could increase the risk of developing serotonin syndrome (see section &ldquo;Other medicines and Vexal XR&rdquo;).</li><li>If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye).</li><li>If you have a history of high blood pressure.</li><li>If you have a history of heart problems.</li><li>If you have been told you have an abnormal heart rhythm.</li><li>If you have a history of fits (seizures).</li><li>If you have a history of low sodium levels in your blood (hyponatraemia).</li><li>If you have a tendency to develop bruises or a tendency to bleed easily (history of bleeding disorders), or if you are taking other medicines that may increase the risk of bleeding e.g., warfarin (used to prevent blood clots).</li><li>If you have a history of, or if someone in your family has had, mania or bipolar disorder (feeling over-excited or euphoric).</li><li>If you have a history of aggressive behaviour. &nbsp;&nbsp;</li><li>If you have a history of bleeding disorders.</li><li>If you are pregnant (see &#39;Pregnancy and breast-feeding&#39;).</li></ul><p>Vexal<strong> </strong>XR may cause a sensation of restlessness or an inability to sit or stand still during the first few weeks of treatment. You should tell your doctor if this happens to you.</p><p><em>Thoughts of suicide and worsening of your depression or anxiety disorder </em></p><p>If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or killing yourself. These thoughts may be increased when you first start taking antidepressants, since these medicines all take time to work, usually about two weeks, but sometimes longer. These thoughts may also occur when your dose is decreased or during discontinuation of treatment with Vexal XR.</p><p>You may be more likely to think like this:</p><ul><li>If you have previously had thoughts about killing yourself or harming yourself.</li><li>If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.</li></ul><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.</p><p>You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p><em>Dry mouth </em></p><p>Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of tooth decay (caries). Therefore, you should take special care in your dental hygiene.</p><p><em>Diabetes </em></p><p>Your blood glucose levels may be altered due to Vexal<strong> </strong>XR. Therefore, the dosage of your diabetes medicines may need to be adjusted.</p><p><em>Sexual problems</em></p><p>Medicines like Vexal<strong> </strong>XR (so called SNRIs) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms have continued after stopping treatment.</p><p><strong>Children and adolescents</strong></p><p>Venlafaxine should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe this medicine for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed this medicine for a patient under 18, and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking venlafaxine. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of this medicine in this age group has not yet been demonstrated.</p><p><strong>Other medicines and </strong><strong>Vexal </strong><strong>XR</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Your doctor should decide whether you can take Vexal<strong> </strong>XR with other medicines.</p><p>Do not start or stop taking any medicines, including those bought without a prescription, natural and herbal remedies, before checking with your doctor or pharmacist.</p><ul><li>Monoamine oxidase inhibitors which are used to treat depression or Parkinson&rsquo;s disease must not be taken with Vexal<strong> </strong>XR. Tell your doctor if you have taken these medicines within the last 14 days. (MAOIs: see the section &ldquo;2. What you need to know before you take Vexal<strong> </strong>XR&rdquo;).</li><li>Serotonin syndrome:</li></ul><p>A potentially life-threatening condition or Neuroleptic Malignant Syndrome (NMS)-like reactions (see section &ldquo;4. Possible Side Effects&rdquo;) may occur with venlafaxine treatment, particularly when taken with other medicines.</p><p>Examples of these medicines include:</p><p>-&nbsp;&nbsp;&nbsp; Triptans (used for migraine)</p><p>-&nbsp;&nbsp;&nbsp; Other medicines to treat depression, for instance SNRIs, SSRIs, tricyclics, or medicines containing lithium</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing amphetamines (used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy and obesity)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing linezolid, an antibiotic (used to treat infections)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing moclobemide, a MAOI (used to treat depression)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing sibutramine (used for weight loss)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing tramadol, fentanyl, tapentadol, pethidine, or pentazocine (used to treat severe pain)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing dextromethorphan (used to treat coughing)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing methadone (used to treat opioid drug addiction or severe pain)</p><p>-&nbsp;&nbsp;&nbsp; Medicines containing methylene blue (used to treat high levels of methaemoglobin in the blood)</p><p>-&nbsp;&nbsp;&nbsp; Products containing St. John&rsquo;s Wort (also called Hypericum perforatum, a natural or herbal remedy used to treat mild depression)</p><p>-&nbsp;&nbsp;&nbsp; Products containing tryptophan (used for problems such as sleep and depression)</p><p>-&nbsp;&nbsp;&nbsp; Antipsychotics (used to treat a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, unclear reasoning and becoming withdrawn)</p><p>Signs and symptoms of serotonin syndrome may include a combination of the following:</p><p>Restlessness, hallucinations, loss of coordination, fast heartbeat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting.</p><p>In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever, fast heartbeat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).</p><p>Tell your doctor immediately, or go to the casualty department at your nearest hospital if you think serotonin syndrome is happening to you.</p><p>You must tell your doctor if you are taking medicines that can affect your heart rhythm.</p><p>Examples of these medicines include:</p><ul><li>Antiarrhythmics such as quinidine, amiodarone, sotalol or dofetilide (used to treat abnormal heart rhythm)</li><li>Antipsychotics such as thioridazine (see also Serotonin syndrome above)</li><li>Antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections)</li><li>Antihistamines (used to treat allergy)</li></ul><p>The following medicines may also interact with Vexal<strong> </strong>XR and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medicines containing:</p><ul><li>Ketoconazole (an antifungal medicine)</li><li>Haloperidol or risperidone (to treat psychiatric conditions)</li><li>Metoprolol (a beta blocker to treat high blood pressure and heart problems)</li></ul><p><strong>Vexal </strong><strong>XR with food, drink and alcohol</strong></p><p>Vexal<strong> </strong>XR should be taken with food (see in section &ldquo;3.&nbsp; How to take Vexal<strong> </strong>XR&rdquo;).</p><p>You should avoid alcohol while you are taking Vexal<strong> </strong>XR.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should use Vexal<strong> </strong>XR only after discussing the potential benefits and the potential risks to your unborn child with your doctor.</p><p>Make sure your doctor knows you are on venlafaxine. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your doctor immediately.</p><p>If you are taking this medicine during pregnancy, in addition to having trouble breathing, another symptom your baby might have when it is born is not feeding properly. If your baby has these symptoms when it is born and you are concerned, contact your doctor who will be able to advise you. &nbsp;</p><p>If you take venlafaxine near the end of your pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor should be aware that you are taking Vexal XR so they can advise you.</p><p>Venlafaxine passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the matter with your doctor, and he/she will decide whether you should stop breast-feeding or stop the therapy with this medicine.</p><p><strong>Driving and using machines </strong></p><p>Do not drive or use any tools or machines until you know how this medicine affects you.</p><p><strong>Vexal XR contains sodium</strong></p><p>Vexal contains sodium. Each prolonged-release hard capsule of Vexal XR 37.5 mg, 75 mg and 150 mg Prolonged-release Hard Capsules contains 0.76 mg, 1.51 mg or 3.02 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>The usual recommended starting dose for treatment of depression, generalised anxiety disorder and social anxiety disorder is 75 mg per day. The dose can be raised by your doctor gradually, and if needed, even up to a maximum dose of 375 mg daily for depression. If you are being treated for panic disorder, your doctor will start with a lower dose (37.5 mg) and then increase the dose gradually. The maximum dose for generalised anxiety disorder, social anxiety disorder and panic disorder is 225 mg/day.</p><p>Take Vexal<strong> </strong>XR at approximately the same time each day, either in the morning or in the evening. Capsules must be swallowed whole with fluid and not opened, crushed, chewed or dissolved.</p><p>Vexal<strong> </strong>XR should be taken with food.</p><p>If you have liver or kidney problems, talk to your doctor, since your dose of this medicine may need to be different.</p><p>Do not stop taking this medicine without talking to your doctor (see the section &ldquo;If you stop taking Vexal<strong> </strong>XR&rdquo;).</p><p><strong>If you take more </strong><strong>Vexal </strong><strong>XR</strong><strong> than you should</strong></p><p>Call your doctor or pharmacist immediately if you take more of this medicine than the amount prescribed by your doctor.</p><p>The symptoms of a possible overdose may include a rapid heartbeat, changes in level of alertness (ranging from sleepiness to coma), blurred vision, seizures or fits, and vomiting.</p><p><strong>&nbsp;If you forget to take </strong><strong>Vexal </strong><strong>XR</strong></p><p>If you miss a dose, take it as soon as you remember. However, if it is time for your next dose, skip the missed dose and take only a single dose as usual. Do not take a double dose to make up for a forgotten dose. Do not take more than the daily amount of Vexal<strong> </strong>XR that has been prescribed for you in one day.</p><p><strong>If you stop taking </strong><strong>Vexal </strong><strong>XR</strong></p><p>Do not stop taking your treatment or reduce the dose without the advice of your doctor even if you feel better. If your doctor thinks that you no longer need venlafaxine, he/she may ask you to reduce your dose slowly before stopping treatment altogether. Side effects are known to occur when people stop using this medicine, especially when it is stopped suddenly or the dose is reduced too quickly. Some patients may experience symptoms such as suicidal thoughts, aggressiveness, tiredness, dizziness, light-headedness, headache, sleeplessness, nightmares, dry mouth, loss of appetite, nausea, diarrhoea, nervousness, agitation, confusion, ringing in the ears, tingling or rarely electric shock sensations, weakness, sweating, seizures, or flu-like symptoms, problems with eyesight and increase in blood pressure (which can cause headache, dizziness, ringing in the ears, sweating, etc).</p><p>Your doctor will advise you on how you should gradually discontinue Vexal<strong> </strong>XR treatment. This can take a period of several weeks or months. In some patients, discontinuation may need to occur very gradually over periods of months or longer. If you experience any of these or other symptoms that are troublesome, ask your doctor for further advice.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If any of the following happen, do not take more venlafaxine. Tell your doctor immediately, or go to the casualty department at your nearest hospital:</p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><ul><li>Swelling of the face, mouth, tongue, throat, hands, or feet, and/or a raised itchy rash (hives), trouble swallowing or breathing</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><ul><li>Chest tightness, wheezing, trouble swallowing or breathing</li><li>Severe skin rash, itching or hives (elevated patches of red or pale skin that often itch)</li><li>Signs and symptoms of serotonin syndrome which may include restlessness, hallucinations, loss of coordination, fast heartbeat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting.</li><li>In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever, fast heartbeat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).</li><li>Signs of infection, such as high temperature, chills, shivering, headaches, sweating, flu-like symptoms. This may be the result of a blood disorder which leads to an increased risk of infection.</li><li>Severe rash, which may lead to severe blistering and peeling of the skin.</li><li>Unexplained muscle pain, tenderness or weakness. This may be a sign of rhabdomyolysis. &nbsp;</li></ul><p><strong>Frequency not known (cannot be estimated from the available data) </strong></p><ul><li>Signs and symptoms of a condition called &ldquo;stress cardiomyopathy&rdquo; which may include chest pain, shortness of breath, dizziness, fainting, irregular heartbeat.</li></ul><p>Other side effects that you should tell your doctor about include (The frequency of these side effects are included in the list &ldquo;Other side effects that may occur&rdquo; below):</p><ul><li>Coughing, wheezing and shortness of breath which may be accompanied by a high temperature</li><li>Black (tarry) stools or blood in stools</li><li>Itchiness, yellow skin or eyes, or dark urine, which may be symptoms of inflammation of the liver (hepatitis)</li><li>Heart problems, such as fast or irregular heart rate, increased blood pressure</li><li>Eye problems, such as blurred vision, dilated pupils</li><li>Nerve problems, such as dizziness, pins and needles, movement disorder (muscle spasms or stiffness), seizures or fits</li><li>Psychiatric problems, such as hyperactivity and feeling unusually overexcited</li><li>Withdrawal effects (see section &ldquo;3. How to take Vexal<strong> </strong>XR, if you stop taking Vexal<strong> </strong>XR&rdquo;).</li><li>Prolonged bleeding - if you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.</li></ul><p>Do not be concerned if you see small white balls or granules in your stools after taking this medicine. Inside Vexal<strong> </strong>XR capsules are spheroids (small white balls) that contain the active ingredient (venlafaxine). These spheroids are released from the capsule into your stomach. As they travel through your stomach and intestines, venlafaxine is slowly released. The spheroid &ldquo;shell&rdquo; does not dissolve and is passed out in your stools. So, even though you may see spheroids in your stools, your dose of medicine has been absorbed.</p><p><strong><em>Other side effects that may occur </em></strong></p><p><strong>Very common (may affect more than 1 in 10 people) </strong></p><ul><li>Dizziness; headache; drowsiness</li><li>Insomnia</li><li>Nausea; dry mouth; constipation</li><li>Sweating (including night sweats)</li></ul><p><strong>Common (may affect up to 1 in 10 people) </strong></p><ul><li>Appetite decreased</li><li>Confusion; feeling separated (or detached) from yourself; lack of orgasm; decreased libido; agitation; nervousness; abnormal dreams</li><li>Tremor; a sensation of restlessness or an inability to sit or stand still; pins and needles; altered taste sensation; increased muscle tonus</li><li>Visual disturbance including blurred vision; dilated pupils; inability of the eye to automatically change focus from distant to near objects</li><li>Ringing in the ears (tinnitus)</li><li>Fast heartbeat; palpitations</li><li>Increase in blood pressure; flushing</li><li>Shortness of breath; yawning</li><li>Vomiting; diarrhoea</li><li>Mild rash; itching</li><li>Increased frequency in urination; inability to pass urine; difficulties passing urine</li><li>Menstrual irregularities such as increased bleeding or increased irregular bleeding; abnormal ejaculation/orgasm (males); erectile dysfunction (impotence)</li><li>Weakness (asthenia); fatigue; chills</li><li>Weight gain; weight loss</li><li>Increased cholesterol</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><ul><li>Over activity, racing thoughts and decreased need for sleep (mania)</li><li>Hallucinations; feeling separated (or detached) from reality; abnormal orgasm; lack of feeling or emotion; feeling over-excited; grinding of the teeth</li><li>Fainting; involuntary movements of the muscles; impaired coordination and balance</li><li>Feeling dizzy (particularly when standing up too quickly); decrease in blood pressure</li><li>Vomiting blood, black tarry stools (faeces) or blood in stools; which can be a sign of internal bleeding</li><li>Sensitivity to sunlight; bruising; abnormal hair loss</li><li>Inability to control urination</li><li>Stiffness, spasms and involuntary movements of the muscles</li><li>Slight changes in blood levels of liver enzymes</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people) </strong></p><ul><li>Seizures or fits</li><li>Coughing, wheezing and shortness of breath which may be accompanied by a high temperature</li><li>Disorientation and confusion often accompanied by hallucination (delirium)</li><li>Excessive water intake (known as SIADH)</li><li>Decrease in blood sodium levels</li><li>Severe eye pain and decreased or blurred vision</li><li>Abnormal, rapid or irregular heartbeat, which could lead to fainting</li><li>Severe abdominal or back pains (which could indicate a serious problem in the gut, liver or pancreas)</li><li>Itchiness, yellow skin or eyes, dark urine, or flu-like symptoms, which are symptoms of inflammation of the liver (hepatitis)</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people) </strong></p><ul><li>Prolonged bleeding, which may be a sign of reduced number of platelets in your blood, leading to an increased risk of bruising or bleeding</li><li>Abnormal breast milk production</li><li>Unexpected bleeding, e.g. bleeding gums, blood in the urine or in vomit, or the appearance of unexpected bruises or broken blood vessels (broken veins)</li></ul><p><strong>Frequency not known (cannot be estimated from the available data) </strong></p><ul><li>Suicidal ideation and suicidal behaviours; cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see in section &ldquo;2. What you need to know before you take Vexal<strong> </strong>XR&rdquo;)</li><li>Aggression</li><li>Vertigo &nbsp;</li><li>Heavy vaginal bleeding shortly after birth (postpartum haemorrhage), (see in section 2 &lsquo;Pregnancy and breast-feeding&rsquo;)</li></ul><p>Venlafaxine sometimes causes unwanted effects that you may not be aware of, such as increases in blood pressure or abnormal heart beat; slight changes in blood levels of liver enzymes, sodium or cholesterol. More rarely, venlafaxine may reduce the function of platelets in your blood, leading to an increased risk of bruising or bleeding. Therefore, your doctor may wish to do blood tests occasionally, particularly if you have been taking venlafaxine for a long time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the packaging after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is venlafaxine hydrochloride.</p><p>Each prolonged-release hard capsule of Vexal XR 37.5 mg Prolonged-release Hard Capsules contains 42.43 mg venlafaxine hydrochloride equivalent to 37.5 mg venlafaxine.</p><p>Each prolonged-release hard capsule of Vexal XR 75 mg Prolonged-release Hard Capsules contains 84.86 mg venlafaxine hydrochloride equivalent to 75 mg venlafaxine.</p><p>Each prolonged-release hard capsule of Vexal XR 150 mg Prolonged-release Hard Capsules contains 169.71 mg venlafaxine hydrochloride equivalent to 150 mg venlafaxine.</p><p>The other ingredients are: Capsule content: <em>Tablet core:</em> Hypromellose, Eudragit powder, sodium lauryl sulfate and magnesium stearate. <em>Tablet coat:</em> Eudragit. Capsule shell: Titanium dioxide, gelatin, red iron oxide (in 75 mg PR capsules only), Erythrosine (in 150 mg PR capsules only) and Indigo carmine (in 150 mg PR capsules only).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vexal XR 37.5 mg Prolonged-release Hard Capsules are white opaque cap-white opaque body, imprinted with “VEN” on the cap and with “37.5” on the body containing one white, round, biconvex 37.5 mg film-coated tablet in opaque white PVC/PE/PVDC/aluminum blisters.

Vexal XR 75 mg Prolonged-release Hard Capsules are flesh opaque cap-flesh opaque body, imprinted with “VEN” on the cap and with “75” on the body containing two white, round, biconvex 37.5 mg film-coated tablets in opaque white PVC/PE/PVDC/aluminum blisters.

Vexal XR 150 mg Prolonged-release Hard Capsules are scarlet opaque cap-scarlet opaque body, imprinted with “VEN” on the cap and with “150” 
on the body containing three white, round, biconvex 50 mg film-coated tablets in opaque white PVC/PE/PVDC/aluminum blisters.
Pack size: 14 Prolonged-release hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: <u>SAPV@hikma.com</u></p><p><strong>Manufacturer and Under licensed from</strong></p><p>Pharmathen International S.A.</p><p>Sapes Industrial Park, Block 5</p><p>69300 Rodopi, Greece</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2021; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ڤيكسال اكس ار على المادة الفعّالة ڤانلافاكسين.</p><p dir="RTL">ڤيكسال اكس ار هو عبارة عن مضاد اكتئاب ينتمي إلى مجموعة أدوية تسمى مثبطات استرداد السيروتونين والنورإبينفرين. تستخدم هذه المجموعة من الأدوية في علاج الاكتئاب وحالات أخرى مثل اضطرابات القلق. يُعتقد أن الأشخاص الذين يعانون من الاكتئاب أو القلق تكون لديهم مستويات أقل من السيروتونين والنورإبنفرين في الدماغ. وطريقة عمل مضادات الاكتئاب غير مفهومة بالكامل، لكنها قد تساعد على زيادة مستويات السيروتونين والنورإبنفرين في الدماغ.</p><p dir="RTL">ڤيكسال اكس ار هو علاج للبالغين الذين يعانون من الاكتئاب. هو أيضاً علاج للبالغين الذين يعانون من اضطرابات القلق التالية: اضطراب القلق العام، اضطراب القلق الاجتماعي (الخوف من المواقف الاجتماعية أو تجنبها)، واضطراب الهلع (نوبات الهلع). تعتبر معالجة حالات الاكتئاب أو اضطرابات القلق مهمة لمساعدتك على التحسن. وفي حال عدم معالجتها، فقد لا تتحسن حالتك وقد تصبح أكثر خطورة وتزداد صعوبة علاجها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ڤيكسال اكس ار </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لڤانلافاكسين أو لأي من المواد الأخرى المستخدمة في تركيبة هذه الدواء (المذكورة في القسم 6).</li><li>إذا كنت تتناول أيضاً، أو تناولت خلال 14 يوماً السابقة، &rlm;أي أدوية معروف عنها أنها من مثبطات أكسيداز أحادي الأمين غير العكسية، والتي يتم استخدامها في علاج الاكتئاب أو مرض باركنسون. يمكن أن يتسبب تناول ڤيكسال اكس ار مع أحد مثبطات أكسيداز أحادي الأمين غير العكسية في حدوث آثار جانبية خطيرة أو مهدّدة للحياة. كما يتعين عليك، قبل أن تأخذ أي مثبط من مثبطات أكسيداز أحادي الأمين، الانتظار لمدة 7 أيام على الأقل من بعد التوقف عن تناول ڤيكسال اكس ار (انظر أيضاً في القسم بعنوان &quot;الأدوية الأخرى وڤيكسال اكس ار&quot; والمعلومات في قسم &quot;متلازمة السيروتونين&quot;).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول ڤيكسال اكس ار:</p><ul dir="rtl"><li>إذا كنت تستخدم أدوية أخرى قد تتسبب عند تناولها مع ڤيكسال اكس ار في زيادة المخاطر المتعلقة بالإصابة بمتلازمة السيروتونين (انظر في قسم &quot;الأدوية الأخرى وڤيكسال اكس ار&quot;).</li><li>إذا كنت تعاني من مشاكل في العين، مثل بعض الأنواع المحددة من الزرقة (زيادة الضغط في العين).</li><li>إذا عانيت في السابق من ارتفاع في ضغط الدم.</li><li>إذا عانيت في السابق من مشاكل في القلب.</li><li>إذا تم إخبارك أنك تعاني من نظم قلبي غير منتظم.</li><li>إذا عانيت في السابق من نوبات (نوبات صرع).</li><li>إذا عانيت في السابق من انخفاض مستويات الصوديوم في الدم (نقص صوديوم الدم).</li><li>إذا كان لديك قابلية التعرّض لكدمات أو قابلية التعرّض للنزيف بسهولة (تاريخ مرضي لاضطرابات نزفية)، أو إذا كنت تتناول أدوية خرى أخرى قد تزيد من خطر النزيف مثل: الوارفارين (دواء يستخدم في منع التجلطات الدموية).</li><li>إذا عانيت سابقاً، أو إذا عانى أحد أفراد أسرتك من الهوس أو اضطراب ثنائي القطب (الشعور بفرط الإثارة أو النشوة).</li><li>إذا عانيت سابقاً من سلوك عدواني.</li><li>إذا عانيت سابقاً من اضطرابات نزفيّة.</li><li>إذا كنت حاملاً (انظري إلى &rsquo;الحمل والرضاعة&lsquo;).</li></ul><p dir="RTL">قد يتسبب ڤيكسال اكس ار في الشعور بالتململ أو عدم القدرة على الجلوس أو الوقوف ثابتاً وذلك في أثناء الأسابيع القليلة الأولى من العلاج. يجب أن تخبر طبيبك إذا حدث هذا الأمر معك.</p><p dir="RTL"><em>التفكير في الانتحار وتفاقم إصابتك بالاكتئاب أو اضطراب القلق</em></p><p dir="RTL">إذا كنت مصاباً بالاكتئاب و/أو اضطرابات القلق، فإنه يمكن أحياناً أن تراودك أفكار بقتل نفسك أو إيذائها. قد تزداد هذه الأفكار عندما تبدأ في تناول مضادات الاكتئاب لأول مرة، حيث إن هذه الأدوية يستغرق جميعها فترة لتحقيق النتيجة المطلوبة، وهذه الفترة عادة ما تبلغ أسبوعين، ولكنها قد تطول عن ذلك أحياناً. قد تحدث هذه الأفكار أيضاً عندما تقل جرعتك أو أثناء التوقف عن العلاج بڤيكسال اكس ار.</p><p dir="RTL">من المرجح أن تفكر بهذه الطريقة بشكل أكبر في&nbsp;الحالات التالية:</p><ul dir="rtl"><li>إذا كانت تراودك في السابق أفكار بإيذاء نفسك أو الانتحار.</li><li>إذا كنت شاباً بالغاً. قد أوضحت المعلومات الواردة من التجارب السريرية وجود مخاطر متزايدة للسلوك الانتحاري عند البالغين من الشباب (أقل من 25 عاماً) المصابين بحالات نفسية وتمت معالجتهم بأحد مضادات الاكتئاب.</li></ul><p dir="RTL">إذا راودتك أفكار بإيذاء نفسك أو قتل نفسك في أي وقت، فاتصل بطبيبك أو اذهب إلى المستشفى على الفور.</p><p dir="RTL">قد تجد أنه من المفيد بالنسبة لك أن تخبر أحد أقاربك أو أصدقائك المقربين بأنك مصاب بالاكتئاب أو باضطراب القلق، وتطلب منه قراءة هذه النشرة. يمكنك أن تطلب منهم أن يخبروك إذا ما كانت حالة إصابتك بالاكتئاب أو القلق تتفاقم، أو إذا كانوا قلقين تجاه تغيرات تطرأ على سلوكك.</p><p dir="RTL"><em>جفاف الفم</em></p><p dir="RTL">تم الإبلاغ عن التعرّض لجفاف الفم في 10% من المرضى الذين تمت معالجتهم بڤانلافاكسين. قد يزيد ذلك من مخاطر الإصابة بتسوس الأسنان (نخر الأسنان). لذلك، يتعيّن عليك الاهتمام بوجه خاص بنظافة أسنانك.</p><p dir="RTL"><em>مرض السكري</em></p><p dir="RTL">قد تتغير لديك مستويات جلوكوز الدم بسبب ڤيكسال اكس ار. لذلك، قد يتطلب الأمر تعديل ما تتناوله من جرعات أدوية مرض السكري.</p><p dir="RTL"><em>المشاكل الجنسية</em></p><p dir="RTL">قد تؤدي الأدوية المماثلة لڤيكسال اكس ار (والتي تسمى بمثبطات استرداد السيروتونين والنورإبينفرين) إلى حدوث أعراض عجز جنسي (انظر في القسم 4). في بعض الحالات، استمرت هذه الأعراض بعد توقف العلاج.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يجب عادة عدم استخدام ڤيكسال اكس ار مع الأطفال والمراهقين دون سن 18 عاماً. كما يجب أن تعرف أن المرضى دون سن 18 عاماً معرّضون بشكل زائد لمخاطر الآثار الجانبية، مثل محاولة الانتحار، التفكير في الانتحار والعدائية (العدوانية المسيطرة، السلوك المعاكس والغضب) وذلك عندما يتناولون هذه الفئة من الأدوية. وعلى الرغم من ذلك، قد يصف طبيبك هذا الدواء للمرضى دون 18 عاماً لأنه قرر أن هذا الدواء هو الأفضل بالنسبة إليهم. إذا وصف طبيبك هذا الدواء لمريض دون سن 18 عاماً، وكنت تريد مناقشة هذا الأمر، فيرجى منك الرجوع إلى طبيبك. يجب أن تخبر طبيبك إذا ظهرت أي من الأعراض المذكورة أعلاه أو تفاقمت عند المرضى دون سن 18 عاماً الذين يتناولون ڤانلافاكسين. كما أنه لم تظهر بعد في هذه الفئة العمرية الآثار الجانبية طويلة المدى لهذا الدواء المتعلقة بالنمو، النضوج والتطور على المستويين السلوكي والمعرفي.</p><p dir="RTL"><strong>الأدوية الأخرى وڤيكسال اكس ار </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">يجب أن يقرر طبيبك ما إذا كان باستطاعتك أن تتناول ڤيكسال اكس ار مع أدوية أخرى.</p><p dir="RTL">لا تبدأ أو تتوقف عن تناول أي أدوية، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية، العلاجات الطبيعية وعلاجات الأعشاب، قبل أن تتحقق من ذلك مع طبيبك أو الصيدلي.</p><ul dir="rtl"><li>لا يجب تناول مثبطات أكسيداز أحادي الأمين المستخدمة في علاج الاكتئاب أو مرض باركنسون مع ڤيكسال اكس ار . أخبر طبيبك إذا تناولت هذه الأدوية خلال 14 يوماً السابقة. (لمعلومات عن مثبطات أكسيداز أحادي الأمين: انظر في القسم &quot;2. ما الذي يجب عليك معرفته قبل تناول ڤيكسال اكس ار&quot;).</li><li>متلازمة السيروتونين:</li></ul><p>قد تحدث ردود فعل يمكن أن تكون مهددة للحياة أو أشبه بالمتلازمة الخبيثة للدواء المضاد للذهان (انظر في القسم &quot;4. الآثار الجانبية المحتملة&quot;) عند العلاج بڤانلافاكسين، وخاصة عند تناوله مع أدوية أخرى.</p><p dir="RTL">بعض الأمثلة على هذه الأدوية تشمل:</p><ul dir="rtl"><li>التريبتانات (المستخدمة في علاج الصداع النصفي)</li><li>الأدوية الأخرى لعلاج الاكتئاب، على سبيل المثال: مثبطات استرداد السيروتونين والنورإبينفرين، مثبطات استرداد السيروتونين الانتقائية، مضادات الاكتئاب ثلاثية الحلقات، أو الأدوية التي تحتوي على اللليثيوم</li><li>الأدوية التي تحتوي على الأمفيتامينات (تستخدم لعلاج اضطراب فرط الحركة ونقص الانتباه، الخدار والسمنة)</li><li>الأدوية التي تحتوي على لينزوليد، وهو مضاد حيوي (يستخدم في علاج العدوى)</li><li>الأدوية التي تحتوي على موكلوبيميد، وهو مثبط أكسيداز أحادي الأمين (يستخدم في علاج الاكتئاب)</li><li>الأدوية التي تحتوي على سيبوترامين (يستخدم في إنقاص الوزن)</li><li>الأدوية التي تحتوي على ترامادول، فنتانيل، تابنتادول، بيثيدين، أو بنتازوسين (وهي تستخدم في علاج الألم الشديد)</li><li>الأدوية التي تحتوي على الدكستروميثورفان (يستخدم في علاج السعال)</li><li>الأدوية التي تحتوي على الميثادون (يستخدم في العلاج من إدمان عقاقير الأفيون أو علاج الألم الشديد)</li><li>الأدوية التي تحتوي على أزرق الميثيلين (يستخدم في علاج مستويات الميثيموجلوبين العالية في الدم)</li><li>المنتجات التي تحتوي على عشبة سانت جون (تسمى أيضاً هايبيريكم بيرفراتم (العرن المثقوب)، وهي علاج طبيعي أو عشبي يستخدم في علاج الاكتئاب الطفيف)</li><li>المنتجات التي تحتوي على تريبتوفان (يستخدم في علاج مشاكل مثل النوم والاكتئاب)</li><li>مضادات الذهان (تستخدم في علاج مرض تصاحبه أعراض مثل سماع أشياء لا وجود لها أو رؤيتها أو الإحساس بها، تبني اعتقادات خاطئة، الشعور بحالة ارتياب غير طبيعية، التفكير المشوش وانطواء المريض على نفسه)</li></ul><p dir="RTL">قد تشمل العلامات والأعراض لمتلازمة السيروتونين مزيجاً مما يلي:<strong> </strong>التململ، الهلوسة، فقدان تنسيق الحركة، سرعة نبضات القلب، ارتفاع درجة حرارة الجسم، تغيرات سريعة في ضغط<strong> </strong>الدم، ردود فعل مفرطة النشاط، إسهال، غيبوبة، غثيان، قيء.</p><p dir="RTL">تشبه أنواع متلازمة السيروتونين الأكثر شدة المتلازمة الخبيثة للأدوية المضادة للذهان. قد تشمل علامات وأعراض المتلازمة الخبيثة للأدوية المضادة للذهان مزيجاً ما بين الحمّى، سرعة نبضات القلب، التعرّق، تيبس العضلات الشديد، الارتباك، زيادة أنزيمات العضلات (التي يحددها اختبار الدم).</p><p dir="RTL">إذا كنت تعتقد أنك تتعرض لمتلازمة السيروتونين، فأبلغ الطبيب فوراً، أو اذهب إلى قسم الطوارئ في أقرب مستشفى منك.</p><p dir="RTL">إذا كنت تتناول أدوية يمكن أن تؤثر على النظم القلبي فيجب عليك أن تخبر طبيبك بذلك.</p><p dir="RTL">&nbsp;بعض الأمثلة على هذه الأدوية تشمل:</p><ul dir="rtl"><li>مضادات اضطراب النظم القلبي مثل الكوينيدين، الأميودارون، السوتالول أو&nbsp; الدوفيتيليد (تستخدم في علاج النظم القلبي غير المنتظم)</li><li>مضادات الذهان مثل الثيوريدازين (انظر أيضاً متلازمة السيروتونين أعلاه)</li><li>مضادات حيوية مثل الإريثرومايسين أو الموكسيفلوكساسين (تستخدم في علاج العدوى البكتيرية)</li><li>مضادات الهستامين (تستخدم في علاج الحساسية)</li></ul><p dir="RTL">قد تتفاعل أيضاً الأدوية التالية مع ڤيكسال اكس ار ويجب استخدامها بحذر. من المهم على نحو خاص أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أدوية تحتوي على:</p><ul dir="rtl"><li>كيتوكونازول (دواء مضاد للفطريات)</li><li>هالوبيريدول أو ريسبيريدون (لعلاج الحالات النفسية)</li><li>ميتوبرولول (أحد حاصرات بيتا ويستخدم لعلاج ارتفاع ضغط الدم ومشاكل القلب)</li></ul><p dir="RTL"><strong>ڤيكسال اكس ار مع الطعام، الشراب والكحول</strong></p><p dir="RTL">يجب تناول ڤيكسال اكس ار مع الطعام (انظر في القسم &quot;3. طريقة تناول ڤيكسال اكس ار&quot;).</p><p dir="RTL">يجب عليك أن تتجنب شرب الكحول عند تناول ڤيكسال اكس ار.</p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة</strong></p><p dir="RTL">يرجى استشارة طبيبك أو الصيدلي إذا كنت حاملاً أو مرضعاً، أو&nbsp; تعتقدين بأنك حاملاً أو تخططين لذلك قبل تناول هذا الدواء.<strong> </strong>يجب استخدم ڤيكسال اكس ار فقط بعد مناقشة الفوائد والمخاطر المحتملة على الجنين مع طبيبك.</p><p dir="RTL">تأكدي من أن طبيبك على علم باستخدامك لڤانلافاكسين. عند استخدامه في أثناء الحمل، فإن الأدوية المشابهة (مثبطات استرداد السيروتونين الانتقائية) قد تزيد من مخاطر حدوث حالة خطرة عند المواليد تسمى فرط التوتر الرئوي المستمر عند حديثي الولادة، وهي تجعل المولود يتنفس بشكل أسرع ويبدو لونه ضارباً إلى الزرقة. تبدأ هذه الأعراض عادة خلال 24 ساعة الأولى بعد الولادة المولود. إذا حدث ذلك مع طفلك فيجب الاتصال بطبيبك على الفور.</p><p dir="RTL">إذا كنت تتناولين هذا الدواء في أثناء الحمل، بالإضافة إلى وجود صعوبة في التنفس، فقد يتعرض المولود إلى عرض آخر عند ولادته ألا وهو عدم تغذيته كما ينبغي. إذا ظهرت هذه الأعراض عند طفلك عند ولادته وكنت قلقة بشأن ذلك، فاتصلي بطبيبك الذي سيكون قادراً على تقديم المشورة لك.</p><p dir="RTL"><strong>&nbsp;</strong>إذا كنتِ تتناولين ڤانلافاكسين في فترة قريبة من نهاية الحمل، فقد يكون هناك خطر متزايد من حدوث نزيف مهبلي غزير بعد الولادة بوقت قصير، خاصة إذا عانيتِ سابقاً من اضطرابات نزفيّة.&nbsp; يجب أن يكون طبيبك على علم بأنك تتناولين ڤيكسال اكس ار حتى يتمكن من تقديم المشورة لك.</p><p dir="RTL">يتسرّب ڤانلافاكسين إلى حليب الثدي. وقد يكون هناك خطر من تأثيره على المولود. لذلك، يجب عليك مناقشة الأمر مع طبيبك والذي بدوره يقرر ما إذا كان عليك التوقف عن الرضاعة الطبيعية أو التوقف عن العلاج بهذا الدواء.</p><p dir="RTL"><strong>تأثير ڤيكسال اكس ار على القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب عليك عدم القيادة أو استعمال أي آلات أو ماكينات حتى تعلم مدى تأثير هذا الدواء عليك.</p><p dir="RTL"><strong>يحتوي ڤيكسال اكس ار على الصوديوم</strong></p><p dir="RTL">يحتوي ڤيكسال اكس ار على الصوديوم. تحتوي كل كبسولة صلبة ممتدة الإطلاق من ڤيكسال اكس ار &nbsp;37,5 ملغم، 75 ملغم و150 ملغم كبسولات صلبة ممتدة الإطلاق على 0,76 ملغم، 1,51 ملغم أو 3,02 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل كبسولة صلبة ممتدة الإطلاق، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء كما وصفه لك طبيبك تماماً. تأكد من طبيبك أو الصيدلي إذا كانت لديك أية استفسارات.</p><p dir="RTL">الجرعة الاعتيادية الموصى بها في بداية علاج الاكتئاب، واضطراب القلق العام واضطراب القلق الاجتماعي هي ٧٥ ملغم في اليوم. يمكن زيادة هذه الجرعة تدريجياً عن طريق طبيبك، حتى أنه يمكن إن لزم الأمر، زيادتها إلى أقصى جرعة والتي تبلغ ٣٧٥ ملغم يومياً لعلاج الاكتئاب. إذا كنت تخضع لعلاج اضطراب الهلع، فسوف يبدأ طبيبك علاجك بجرعة منخفضة (٣٧٫٥ ملغم) ثم يبدأ في زيادة الجرعة تدريجياً. تبلغ أقصى جرعة لاضطراب القلق العام، اضطراب القلق الاجتماعي واضطراب الهلع ٢٢٥ ملغم/اليوم.</p><p dir="RTL">يجب تناول ڤيكسال اكس ار في نفس الموعد تقريباً من كل يوم، سواء في الصباح أو في المساء. يجب بلع الكبسولات بالكامل مع سائل وعدم فتحها، سحقها، مضغها أو إذابتها.</p><p dir="RTL">يجب تناول ڤيكسال اكس ار مع الطعام.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد أو الكلى، فتحدث مع طبيبك، حيث قد تكون هناك حاجة إلى جرعة مختلفة من هذا الدواء.</p><p dir="RTL">لا تتوقف عن تناول هذا الدواء دون استشارة طبيبك (انظر القسم &quot;إذا توقفت عن تناول ڤيكسال اكس ار&quot;).</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ڤيكسال اكس ار </strong></p><p dir="RTL">اتصل فوراً بطبيبك أو الصيدلي إذا تناولت جرعة زائدة من هذا الدواء أكبر من الجرعة التي وصفها لك طبيبك.</p><p dir="RTL">قد تشمل أعراض الجرعة الزائدة المحتملة نبضات قلب سريعة، تغيرات في مستوى الانتباه (تتراوح ما بين النعاس إلى الغيبوبة)، رؤية مشوشة، نوبات أو نوبات صرع، وقيء.</p><p dir="RTL"><strong>إذا نسيت تناول ڤيكسال اكس ار </strong></p><p dir="RTL">إذا نسيت تناول جرعة، فتناولها فور تذكرها. مع ذلك، إذا حان وقت الجرعة التالية، فتجاوز الجرعة المنسية ولا تتناول سوى جرعة واحدة كالمعتاد. لا تقم بتناول جرعة مضاعفة للتعويض عن الجرعة المنسية. لا تتناول أكثر من الجرعة اليومية من ڤيكسال اكس ار التي تم وصفها لك طبياً لتناولها في اليوم الواحد.</p><p dir="RTL"><strong>إذا توقفت عن تناول ڤيكسال اكس ار </strong></p><p dir="RTL">لا تتوقف عن تناول علاجك ولا تقم بتغيير الجرعة بدون استشارة طبيبك حتى إذا شعرت بتحسن. إذا كان طبيبك يعتقد أنك لم تعد بحاجة إلى تناول ڤانلافاكسين، فقد يطلب منك تقليل جرعتك ببطء قبل التوقف عن العلاج بالكامل. من المعروف ظهور آثار جانبية عند توقف الأشخاص عن تناول هذا الدواء، خاصة إذا تم إيقافه بشكل مفاجئ أو تم تقليل الجرعة بشكل سريع للغاية. قد يظهر عند بعض المرضى أعراض مثل: الأفكار الانتحارية، العدوانية، التعب، الدوخة، الدوار، الصداع، الأرق، الكوابيس، جفاف الفم، فقدان الشهية، الغثيان، الإسهال، التوتر العصبي، الهياج، الارتباك، الطنين في الأذن، الوخز أو الإحساس بصدمات كهربائية نادرة، الضعف، التعرّق، نوبات الصرع، أو الأعراض المشابهة للإنفلونزا، مشاكل في الرؤية، وزيادة في ضغط الدم (والذي قد يسبب صداع، دوخة، طنين في الأذنين، تعرق، الخ).</p><p dir="RTL">سوف ينصحك طبيبك بطريقة الانقطاع تدريجياً عن العلاج بڤيكسال اكس ار. قد يستغرق ذلك فترة من عدة أسابيع أو أشهر. في بعض المرضى، قد يحتاج التوقف عن العلاج بشكل تدريجي للغاية على فترة أشهر أو أكثر. إذا ظهرت عليك أي من هذه الأعراض أو أعراض أخرى مزعجة، فاطلب استشارة إضافية من طبيبك.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">وفي حال حدوث أي مما يلي، لا تتناول المزيد من ڤانلافاكسين. أخبر طبيبك على الفور، أو توجه إلى قسم الطوارئ في أقرب مستشفى منك:</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 من كل ١٠٠ شخص)</strong></p><ul dir="rtl"><li>تورّم الوجه، الفم، اللسان، الحلق، اليدين، أو القدمين، و/أو طفح جلدي بارز مثير للحكة (شرى)، صعوبة في البلع أو التنفس.</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص)</strong></p><ul dir="rtl"><li>ضيق الصدر، إحداث صوت صفير أثناء التنفس، صعوبة في البلع أو التنفس.</li><li>طفح جلدي شديد، حكة أو شرى (بقع بارزة على الجلد حمراء أو شاحبة وتسبب الحكة في الغالب)</li><li>علامات وأعراض متلازمة السيروتونين التي قد تشمل التململ، الهلوسة، فقدان تنسيق الحركة، سرعة نبضات القلب، ارتفاع درجة حرارة الجسم، تغيرات سريعة في ضغط الدم، ردود فعل مفرطة النشاط، إسهال، غيبوبة، غثيان، قيء.</li><li>تشبه أنواع متلازمة السيروتونين الأكثر شدة المتلازمة الخبيثة للأدوية المضادة للذهان. قد تشمل علامات وأعراض المتلازمة الخبيثة للأدوية المضادة للذهان مزيجاً ما بين الحمّى، سرعة نبضات القلب، التعرّق، تيبس العضلات الشديد، الارتباك، زيادة أنزيمات العضلات (التي يحددها اختبار الدم).</li><li>علامات العدوى، مثل ارتفاع درجة حرارة الجسم، حالات القشعريرة، الارتعاد، الصداع، التعرّق، الأعراض المشابهة للإنفلونزا. قد يكون ذلك نتيجة اضطراب الدم الذي يؤدي إلى زيادة خطر العدوى.</li><li>طفح جلدي شديد، والذي يؤدي إلي تقرّح الجلد وتقشره بشكل شديد.</li><li>ألم بالعضلات، تعب أو ضعف لأسباب غير معلومة. قد يكون ذلك من أعراض انحلال الربيدات.</li></ul><p dir="RTL"><strong>غير معروفة التكرار (لا يمكن تقدير تكرارها من البيانات المتاحة) </strong></p><ul dir="rtl"><li>علامات وأعراض لحالة تسمى &quot;اعتلال أو إجهاد عضلة القلب&quot; والذي قد يتضمن ألم في الصدر، ضيق في التنفس، دوخة، إغماء، اختلال ضربات القلب.</li></ul><p dir="RTL">تشمل الآثار الجانبية الأخرى التي يجب عليك أن تخبر طبيبك بها (تكرار هذه الآثار الجانبية مذكور في القائمة أدناه &quot;الآثار الجانبية الأخرى التي قد تحدث&quot;):</p><ul dir="rtl"><li>السعال، إحداث صوت صفير أثناء التنفس وضيق التنفس الذي يكون مصحوباً بارتفاع درجة حرارة الجسم</li><li>براز أسود (قطراني) أو وجود دم في البراز</li><li>حكة، اصفرار الجلد أو العينين، أو بول داكن اللون والتي قد تمثل أعراض التهاب الكبد (التهاب الكبد الوبائي)</li><li>مشاكل في القلب، مثل سرعة أو عدم انتظام معدل نبضات القلب، زيادة ضغط الدم</li><li>مشاكل في العينين، مثل الرؤية المشوشة، الحدقة المتوسعة</li><li>لمشاكل العصبية، مثل الدوخة، الشعور بالوخز والتنميل، الاضطراب الحركي (التقلصات العضلية أو التيبس)، نوبات الصرع أو النوبات</li><li>المشاكل النفسية، مثل فرط النشاط والشعور بفرط الإثارة بشكل غير طبيعي</li><li>الآثار الانسحابية (انظر القسم &quot;3. طريقة تناول ڤيكسال اكس ار&quot;، و &quot;إذا توقفت عن تناول ڤيكسال اكس ار&quot;).</li><li>النزيف لفترات طويلة - إذا قمت بإصابة أو جرح نفسك، فقد يستغرق توقف النزيف وقتاً أطول من الوقت المعتاد بقليل.</li></ul><p dir="RTL">لا تقلق إذا رأيت حبيبات أو كرات بيضاء صغيرة في برازك بعد تناول هذا الدواء. توجد أجسام كروية الشكل (كرات بيضاء صغيرة) في كبسولات ڤيكسال اكس ار والتي تحتوي على المادة الفعّالة (ڤانلافاكسين). تخرج هذه الأجسام الكروية من الكبسولة وتنتقل إلى معدتك. فبينما تتحرك داخل المعدة والأمعاء، يتم إطلاق ڤانلافاكسين ببطء. ولا يتحلل &quot;غلاف&quot; هذه الأجسام الكروية وتخرج في البراز. وبالتالي، فعلى الرغم من أنك قد ترى الأجسام الكروية في برازك، إلا أنه يتم امتصاص جرعتك من الدواء.</p><p dir="RTL"><strong><em>الآثار الجانبية الأخرى التي قد تحدث</em></strong></p><p dir="RTL"><strong>آثار شائعة جداً (قد تؤثر على أكثر من 1 من كل ١٠ أشخاص)</strong></p><ul dir="rtl"><li>الدوخة؛ الصداع؛ النعاس</li><li>الأرق</li><li>الغثيان؛ جفاف الفم؛ الإمساك</li><li>التعرّق (بما في ذلك التعرّق أثناء الليل)</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى 1 من كل ١٠ أشخاص)</strong></p><ul dir="rtl"><li>فقدان الشهية</li><li>التشوش؛ الشعور بالانفصال (أو الانفصام)؛ انعدام الوصول إلى هزة الجماع؛ انخفاض الرغبة الجنسية؛ الهياج؛ التوتر العصبي؛ الأحلام غير الطبيعية</li><li>الرجفان؛ الشعور بالتململ أو عدم القدرة على الجلوس أو الوقوف بثبات؛ الشعور بالتنميل والوخز؛ تغير الإحساس بالمذاق؛ زيادة توتر العضلات</li><li>الاضطرابات البصرية التي تشمل الرؤية المشوشة؛ الحدقة المتوسعة؛ عدم قدرة العين على تغيير التركيز تلقائياً من الأجسام البعيدة إلى الأجسام القريبة</li><li>طنين في الأذن (طنين)</li><li>سرعة نبضات القلب؛ خفقان</li><li>زيادة في ضغط الدم؛ التورّد</li><li>ضيق التنفس؛ التثاؤب</li><li>القيء؛ الإسهال</li><li>طفح جلدي طفيف؛ حكة</li><li>زيادة معدل التبول؛ عدم القدرة على التبول؛ صعوبة في التبول</li><li>عدم انتظام الدورة الشهرية مثل زيادة النزيف أو زيادة النزيف غير المنتظم؛ عدم انتظام القذف/النشوة الجنسية (عند الذكور)؛ ضعف الانتصاب (العجز الجنسي)</li><li>الضعف (الوهن)؛ الإرهاق؛ حالات القشعريرة</li><li>زيادة الوزن؛ فقدان الوزن</li><li>زيادة الكوليسترول</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 من كل ١٠٠ شخص)</strong></p><ul dir="rtl"><li>فرط النشاط، أنماط التفكير السريع وانخفاض الحاجة إلى النوم (الهوس)</li><li>الهلوسة؛ الشعور بالانفصال (أو الانفصام) عن الواقع؛ هزة الجماع غير الطبيعية؛ انعدام الشعور أو العاطفة؛ الشعور بفرط الإثارة؛ صرير الأسنان</li><li>الإغماء؛ حركات العضلات اللاإرادية؛ اعتلال التنسيق الحركي والتوازن</li><li>الشعور بالدوخة (وخاصة عند الوقوف بسرعة)؛ انخفاض ضغط الدم</li><li>قيء الدم، البراز القطراني الأسود أو وجود دم في البراز؛ الذي يمكن أن يكون علامة للنزيف الداخلي</li><li>الحساسية لضوء الشمس؛ التكدّم، تساقط الشعر بطريقة غير معتادة</li><li>عدم القدرة على التحكم في التبول</li><li>التيبس، التشنجات والحركات اللاإرادية للعضلات</li><li>تغيرات طفيفة في مستويات الدم لأنزيمات الكبد</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص)</strong></p><ul dir="rtl"><li>نوبات صرع أو نوبات</li><li>سعال، إحداث صوت صفير أثناء التنفس وضيق التنفس الذي قد يكون مصحوباً بارتفاع درجة حرارة الجسم</li><li>توهان وارتباك مصحوب عادة بهلوسة (هذيان)</li><li>الاستهلاك المفرط للمياه (المعروف باسم متلازمة إفراز الهرمون المضاد لإدرار البول)</li><li>انخفاض مستويات الصويوم في الدم</li><li>الآم شديدة في العين ورؤية مشوشة أو محدودة</li><li>نبضات قلب غير منتظمة، أو سريعة أو غير طبيعية والتي قد تؤدي إلى الإغماء</li><li>آلام شديدة في منطقة البطن أو الظهر (والتي قد تشير إلى وجود مشكلة خطيرة في الأمعاء، الكبد أو البنكرياس)</li><li>حكة، اصفرار الجلد أو العينين، بول داكن اللون، أو أعراض مشابهة للإنفلونزا وهي أعراض لالتهاب الكبد (التهاب الكبد الوبائي)</li></ul><p dir="RTL"><strong>نادرة جداً (قد تؤثر على ما يصل إلى 1 من كل 10000 شخص)</strong></p><ul dir="rtl"><li>النزيف لفترات طويلة، والذي قد يكون علامة على انخفاض عدد الصفائح الدموية في الدم، وهو ما قد يؤدي إلى زيادة مخاطر التكدم أو النزيف</li><li>إفراز غير طبيعي لحليب الثدي</li><li>نزيف غير متوقع، مثل نزيف اللثة، وجود دم في البول أو في القيء، أو ظهور كدمات غير متوقعة أو وجود أوعية دموية متكسرة (الأوردة المكسورة).</li></ul><p dir="RTL"><strong>غير معروفة التكرار (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>الميل إلى الانتحار والسلوكيات الانتحارية؛ حيث تم الإبلاغ عن وجود حالات ميل إلى الانتحار وسلوكيات انتحارية أثناء العلاج بڤانلافاكسين أو مبكراً عد انقطاع العلاج (انظر في القسم &quot;2. ما الذي يجب عليك معرفته قبل تناول ڤيكسال اكس ار&quot;).</li><li>العدوانية</li><li>الدوار</li><li>نزيف مهبلي غزير بعد الولادة بوقت قصير (نزيف بعد الولادة)، (انظري في قسم 2 &rsquo;الحمل والرضاعة&lsquo;</li></ul><p dir="RTL">أحياناً ما يتسبب ڤانلافاكسين في حدوث تأثيرات غير مرغوب فيها قد لا تكون على دراية بها مثل زيادة ضغط الدم أو نبضات القلب غير الطبيعية؛ تغيرات طفيفة في مستويات الدم لأنزيمات الكبد، أو الصوديوم أو الكوليسترول. قد يتسبب ڤانلافاكسين، على نحو أكثر ندرة، في الحد من وظائف الصفائح الدموية في الدم، وهو ما يؤدي إلى زيادة مخاطر التعرّض لنزيف أو تكدّم. لذلك، قد يطلب منك طبيبك إجراء فحوصات دم من وقت لآخر، خاصة إذا كنت تتناول ڤانلافاكسين لفترة طويلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي هيدروكلوريد الڤانلافاكسين.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من ڤيكسال اكس ار 37.5 ملغم كبسولات صلبة ممتدة الإطلاق على 42.43 ملغم هيدروكلوريد الڤانلافاكسين يكافئ 37.5 ملغم ڤانلافاكسين.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من ڤيكسال اكس ار 75 ملغم كبسولات صلبة ممتدة الإطلاق على 84.86 ملغم هيدروكلوريد الڤانلافاكسين يكافئ 75 ملغم ڤانلافاكسين.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من ڤيكسال اكس ار 150 ملغم كبسولات صلبة ممتدة الإطلاق على 169.71 ملغم هيدروكلوريد الڤانلافاكسين يكافئ 150 ملغم ڤانلافاكسين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي:</p><p dir="RTL">محتوى الكبسولة: <em>لب القرص:</em> هيبروميللوز، مسحوق إيودراجيت، كبريتات لوريل الصوديوم وستيرات المغنيسيوم. <em>غلاف القرص: </em>إيودراجيت. غلاف الكبسولة: ثاني أكسيد التيتانيوم، جيلاتين، أكسيد الحديد الأحمر (فقط في كبسولات ممتدة الإطلاق من 75 ملغم)، إريثروسين (فقط في كبسولات ممتدة الإطلاق من 150 ملغم) وقرمز نيلي (فقط في كبسولات ممتدة الإطلاق من 150 ملغم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ڤيكسال اكس ار 37.5 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات ذات غطاء لونه أبيض غير شفاف وجسم لونه أبيض غير شفاف، مطبوع على الغطاء &quot;VEN&quot; و&quot;37.5&quot; على جسم الكبسولة، تحتوي على قرص واحد بتركيز 37.5 ملغم لونه أبيض، دائري الشكل، ثنائي التحدّب مغطى بطبقة رقيقة داخل أشرطة بيضاء اللون غير شفافة من كلوريد متعدد الڤينيل/متعدد الإيثيلين/ثنائي كلوريد متعدد الڤينيليدين/الألومينيوم.</p><p dir="RTL">ڤيكسال اكس ار 75 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات ذات غطاء لونه لحمي غير شفاف وجسم لونه لحمي غير شفاف، مطبوع على الغطاء &quot;VEN&quot; و&quot;75&quot; على جسم الكبسولة، تحتوي على قرصين بتركيز 37.5 ملغم لونهم أبيض، دائريا الشكل، ثنائيا التحدّب مغطيان بطبقة رقيقة داخل أشرطة بيضاء اللون غير شفافة من كلوريد متعدد الڤينيل/متعدد الإيثيلين/ثنائي كلوريد متعدد الڤينيليدين/الألومينيوم.</p><p dir="RTL">ڤيكسال اكس ار 150 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات ذات غطاء لونه قرمزي غير شفاف وجسم لونه قرمزي غير شفاف، مطبوع على الغطاء &quot;VEN&quot; و&quot;150&quot; على جسم الكبسولة، تحتوي على ثلاث أقراص بتركيز 50 ملغم لونهم أبيض، دائريين الشكل، ثنائيين التحدّب مغطاة بطبقة رقيقة داخل أشرطة بيضاء اللون غير شفافة من كلوريد متعدد الڤينيل/متعدد الإيثيلين/ثنائي كلوريد متعدد الڤينيليدين/الألومينيوم.</p><p dir="RTL">حجم العبوة: 14 كبسولة صلبة ممتدة الإطلاق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة وبترخيص من </strong></p><p dir="RTL">فارماثين الدولية</p><p dir="RTL">سابس بارك الصناعية، مبنى رقم 5</p><p dir="RTL">69300 رودوبي، اليونان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2021؛ رقم النسخة SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vexal XR 37.5 mg Prolonged-release Hard Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each prolonged-release hard capsule contains 42.43 mg venlafaxine hydrochloride equivalent to 37.5 mg venlafaxine.
Excipient with known effect: Sodium. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release hard capsules.
White opaque cap-white opaque body, imprinted with “VEN” on the cap and with “37.5” on the body containing one white, round, biconvex 37.5 mg film-coated tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Treatment of major depressive episodes.</li><li>For prevention of recurrence of major depressive episodes.</li><li>Treatment of generalised anxiety disorder.</li><li>Treatment of social anxiety disorder.</li><li>Treatment of panic disorder, with or without agoraphobia.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><u>Major depressive episodes</u></p><p>The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during the current episode.</p><p>Antidepressive medicinal products should continue for at least six months following remission.</p><p><u>Generalised anxiety disorder</u></p><p>The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p><u>Social anxiety disorder</u></p><p>The recommended dose for prolonged-release venlafaxine is 75 mg given once daily. There is no evidence that higher doses confer any additional benefit.</p><p>However, in individual patients not responding to the initial 75 mg/day, increases up to a maximum dose of 225 mg/day may be considered. Dosage increases can be made at intervals of 2 weeks or more.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p><u>Panic disorder</u></p><p>It is recommended that a dose of 37.5 mg/day of prolonged-release venlafaxine be used for 7 days. Dosage should then be increased to 75 mg/day. Patients not responding to the 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p><u>Elderly patients</u></p><p>No specific dose adjustments of venlafaxine are considered necessary based on patient age alone. However, caution should be exercised in treating the elderly (e.g., due to the possibility of renal impairment, the potential for changes in neurotransmitter sensitivity and affinity occurring with aging). The lowest effective dose should always be used, and patients should be carefully monitored when an increase in the dose is required.</p><p><u>Paediatric population</u></p><p>Venlafaxine is not recommended for use in children and adolescents.</p><p>Controlled clinical studies in children and adolescents with major depressive disorder failed to demonstrate efficacy and do not support the use of venlafaxine in these patients (see sections 4.4 and 4.8).</p><p>The efficacy and safety of venlafaxine for other indications in children and adolescents under the age of 18 have not been established.</p><p><u>Patients with hepatic impairment</u></p><p>In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be considered. However, due to inter-individual variability in clearance, individualisation of dosage may be desirable.</p><p>There are limited data in patients with severe hepatic impairment. Caution is advised, and a dose reduction by more than 50% should be considered. The potential benefit should be weighed against the risk in the treatment of patients with severe hepatic impairment.</p><p><u>Patients with renal impairment</u></p><p>Although no change in dosage is necessary for patients with glomerular filtration rate (GFR) between 30-70 ml/minute, caution is advised. For patients that require haemodialysis and in patients with severe renal impairment (GFR &lt;30 ml/min), the dose should be reduced by 50%. Because of inter-individual variability in clearance in these patients, individualisation of dosage may be desirable.</p><p><u>Withdrawal symptoms seen on discontinuation of venlafaxine</u></p><p>Abrupt discontinuation should be avoided. When stopping treatment with venlafaxine, the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). However, the time period required for tapering and the amount of dose reduction may depend on the dose, duration of therapy and the individual patient. In some patients, discontinuation may need to occur very gradually over periods of months or longer. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p><strong>Method of administration</strong></p><p>For oral use.</p><p>It is recommended that venlafaxine prolonged-release capsules be taken with food, at approximately the same time each day. Capsules must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.</p><p>Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine prolonged-release capsules at the nearest equivalent daily dosage. For example, venlafaxine immediate-release tablets 37.5 mg twice daily may be switched to venlafaxine prolonged-release capsules 75 mg once daily. Individual dosage adjustments may be necessary.</p><p>Venlafaxine prolonged-release capsules contain spheroids, which release the active substance slowly into the digestive tract. The insoluble portion of these spheroids is eliminated and may be seen in faeces.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI.
Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Suicide/suicidal thoughts or clinical worsening</u></p><p>Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which venlafaxine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Close supervision of patients, and in particular those at high risk, should accompany drug therapy, especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour, and to seek medical advice immediately if these symptoms present.</p><p><u>Paediatric population</u></p><p>Venlafaxine should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p><u>Serotonin syndrome</u></p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition may occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, amphetamines, lithium, sibutramine, St. John&#39;s Wort [Hypericum perforatum], fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such as tryptophan supplements) or with antipsychotics or other dopamine antagonists (see sections 4.3 and 4.5).</p><p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea). Serotonin syndrome in its most severe form, can resemble NMS, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs and mental status changes.</p><p>If concomitant treatment with venlafaxine and other agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p><p>The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended.</p><p><u>Narrow-angle glaucoma</u></p><p>Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised intraocular pressure or patients at risk for acute narrow-angle glaucoma (angle-closure glaucoma) be closely monitored.</p><p><u>Blood pressure</u></p><p>Dose-related increases in blood pressure have been commonly reported with venlafaxine. In some cases, severely elevated blood pressure requiring immediate treatment has been reported in postmarketing experience. All patients should be carefully screened for high blood pressure and pre-existing hypertension should be controlled before initation of treatment. Blood pressure should be reviewed periodically, after initiation of treatment and after dose increases. Caution should be exercised in patients whose underlying conditions might be compromised by increases in blood pressure, e.g., those with impaired cardiac function.</p><p><u>Heart rate</u></p><p>Increases in heart rate can occur, particularly with higher doses. Caution should be exercised in patients whose underlying conditions might be compromised by increases in heart rate.</p><p><u>Cardiac disease and risk of arrhythmia</u></p><p>Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, it should be used with caution in these patients.</p><p>In postmarketing experience, cases of QTc prolongation, Torsade de Pointes (TdP), ventricular tachycardia, and fatal cardiac arrhythmias have been reported with the use of venlafaxine, especially in overdose or in patients with other risk factors for QTc prolongation/TdP. The balance of risks and benefits should be considered before prescribing venlafaxine to patients at high risk of serious cardiac arrhythmia or QTc prolongation (see section 5.1).</p><p><u>Convulsions</u></p><p>Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be introduced with caution in patients with a history of convulsions, and concerned patients should be closely monitored. Treatment should be discontinued in any patient who develops seizures.</p><p><u>Hyponatraemia</u></p><p>Cases of hyponatraemia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion may occur with venlafaxine. This has most frequently been reported in volume-depleted or dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise volume-depleted may be at greater risk for this event.</p><p><u>Abnormal bleeding</u></p><p>Medicinal products that inhibit serotonin uptake may lead to reduced platelet function. Bleeding events related to SSRI and SNRI use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to gastrointestinal and life-threatening haemorrhages. The risk of haemorrhage may be increased in patients taking venlafaxine. As with other serotonin-reuptake inhibitors, venlafaxine should be used cautiously in patients predisposed to bleeding, including patients on anticoagulants and platelet inhibitors.</p><p><u>Serum cholesterol</u></p><p>Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled clinical trials. Measurement of serum cholesterol levels should be considered during long-term treatment.</p><p><u>Co-administration with weight loss agents</u></p><p>The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Co-administration of venlafaxine and weight loss agents is not recommended. Venlafaxine is not indicated for weight loss alone or in combination with other products.</p><p><u>Mania/hypomania</u></p><p>Mania/hypomania may occur in a small proportion of patients with mood disorders who have received antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used cautiously in patients with a history or family history of bipolar disorder.</p><p><u>Aggression</u></p><p>Aggression may occur in some patients who have received antidepressants, including venlafaxine. This has been reported under initiation, dose changes and discontinuation of treatment.</p><p>As with other antidepressants, venlafaxine should be used cautiously in patients with a history of aggression.</p><p><u>Discontinuation of treatment</u></p><p>Discontinuation effects are well known to occur with antidepressants, and sometimes these effects can be protracted and severe. Suicide/suicidal thoughts and aggression have been observed in patients during changes in venlafaxine dosing regimen, including during discontinuation. Therefore, patients should be closely monitored when the dose is reduced or during discontinuation (see above in section 4.4 - Suicide/suicidal thoughts or clinical worsening, and Aggression).Withdrawal symptoms, when treatment is discontinued, are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation (tapering and post-tapering) occurred in approximately 31% of patients treated with venlafaxine and 17% of patients taking placebo.</p><p>The risk of withdrawal symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, headache, visual impairment and hypertension are the most commonly reported reactions. Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that venlafaxine should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see section 4.2). In some patients, discontinuation could take months or longer.</p><p><u>Sexual dysfunction</u></p><p>Serotonin-norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SNRIs.</p><p><u>Akathisia/psychomotor restlessness</u></p><p>The use of venlafaxine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p><u>Dry mouth</u></p><p>Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of caries, and patients should be advised upon the importance of dental hygiene.</p><p><u>Diabetes</u></p><p>In patients with diabetes, treatment with an SSRI or venlafaxine may alter glycaemic control. Insulin and/or oral antidiabetic dosage may need to be adjusted.</p><p><u>Haemorrhage</u></p><p>SSRIs/SNRIs may increase the risk of postpartum haemorrhage (see sections 4.6, 4.8).</p><p><u>Drug-Laboratory Test Interactions</u></p><p>False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.</p><p><u>Vexal XR contains sodium </u></p><p>Vexal contains sodium. Each prolonged-release hard capsule contains 0.76 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monoamine Oxidase Inhibitors (MAOI)</u></p><p><em>Irreversible non-selective MAOIs</em></p><p>Venlafaxine must not be used in combination with irreversible non-selective MAOIs. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible non-selective MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible non-selective MAOI (see sections 4.3 and 4.4).</p><p><em>Reversible, selective MAO-A inhibitor (moclobemide)</em></p><p>Due to the risk of serotonin syndrome, the combination of venlafaxine with a reversible and selective MAOI, such as moclobemide, is not recommended. Following treatment with a reversible MAO-inhibitor, a shorter withdrawal period than 14 days may be used before initiation of venlafaxine treatment. It is recommended that venlafaxine should be discontinued for at least 7 days before starting treatment with a reversible MAOI (see section 4.4).</p><p><em>Reversible, non-selective MAOI (linezolid)</em></p><p>The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to patients treated with venlafaxine (see section 4.4).</p><p>Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death.</p><p><u>Serotonin syndrome</u></p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, amphetamines, lithium, sibutramine, St. John&#39;s Wort [<em>Hypericum perforatum</em>], fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such as tryptophan supplements) or with antipsychotics or other dopamine antagonists (see sections 4.3 and 4.4).</p><p>If concomitant treatment with venlafaxine and an SSRI, an SNRI or a serotonin receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see section 4.4).</p><p><u>CNS-active substances</u></p><p>The risk of using venlafaxine in combination with other CNS-active substances has not been systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination with other CNS-active substances.</p><p><u>Ethanol</u></p><p>Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active substances, patients should be advised to avoid alcohol consumption.</p><p><u>Drugs that Prolong the QT Interval</u></p><p>The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with concomitant use of other medicinal products which prolong the QTc interval. Co-administration of such medicinal products should be avoided (see section 4.4).</p><p>Relevant classes include:</p><ul><li>Class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol, dofetilide)</li><li>Some antipsychotics (e.g. thioridazine)</li><li>Some macrolides (e.g. erythromycin)</li><li>Some antihistamines</li><li>Some quinolone antibiotics (e.g. moxifloxacin)</li></ul><p>The above list is not exhaustive and other individual medicinal products known to significantly increase QT interval should be avoided.</p><p><u>Effect of other medicinal products on venlafaxine</u></p><p><em>Ketoconazole (CYP3A4 inhibitor)</em></p><p>A pharmacokinetic study with ketoconazole in CYP2D6 extensive (EM) and poor metabolisers (PM) resulted in higher AUC of venlafaxine (70% and 21% in CYP2D6 PM and EM subjects, respectively) and O-desmethylvenlafaxine (33% and 23% in CYP2D6 PM and EM subjects, respectively) following administration of ketoconazole. Concomitant use of CYP3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir, ritonavir, saquinavir, telithromycin) and venlafaxine may increase levels of venlafaxine and O-desmethylvenlafaxine. Therefore, caution is advised if a patient&#39;s therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.</p><p><u>Effect of venlafaxine on other medicinal products</u></p><p><em>Lithium</em></p><p>Serotonin syndrome may occur with the concomitant use of venlafaxine and lithium (see Serotonin syndrome).</p><p><em>Diazepam</em></p><p>Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active metabolite, desmethyldiazepam. Diazepam does not appear to affect the pharmacokinetics of either venlafaxine or O-desmethylvenlafaxine. It is unknown whether a pharmacokinetic and/or pharmacodynamic interaction with other benzodiazepines exists.</p><p><em>Imipramine</em></p><p>Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. There was a dose-dependent increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold when venlafaxine 75 mg to 150 mg daily was administered. Imipramine did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine.<strong>&nbsp;</strong>The clinical significance of this interaction is unknown. Caution should be exercised with co-administration of venlafaxine and imipramine.</p><p><em>Haloperidol</em></p><p>A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70% increase in AUC, an 88% increase in C<sub>max</sub>, but no change in half-life for haloperidol. This should be taken into account in patients treated with haloperidol and venlafaxine concomitantly. The clinical significance of this interaction is unknown.</p><p><em>Risperidone</em></p><p>Venlafaxine increased the risperidone AUC by 50%, but did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). The clinical significance of this interaction is unknown.</p><p><em>Metoprolol</em></p><p>Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic interaction study for both medicinal products resulted in an increase of plasma concentrations of metoprolol by approximately 30-40% without altering the plasma concentrations of its active metabolite, &alpha;-hydroxymetoprolol. The clinical relevance of this finding in hypertensive patients is unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine. Caution should be exercised with co-administration of venlafaxine and metoprolol.</p><p><em>Indinavir</em></p><p>A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in C<sub>max</sub> for indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine. The clinical significance of this interaction is unknown.</p><p><em>Drugs Metabolized by Cytochrome P450 Isoenzymes</em></p><p>In vivo studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP3A4 (alprazolam and carbamazepine), CYP1A2 (caffeine), and CYP2C9 (tolbutamide) or CYP2C19 (diazepam) in vivo.</p><p><em>Oral contraceptives</em></p><p>In post-marketing experience unintended pregnancies have been reported in subjects taking oral contraceptives while on venlafaxine. There is no clear evidence these pregnancies were a result of drug interaction with venlafaxine. No interaction study with hormonal contraceptives has been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy Category C.</p><p>There are no adequate data from the use of venlafaxine in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Venlafaxine must only be administered to pregnant women if the expected benefits outweigh any possible risk.</p><p>As with other serotonin reuptake inhibitors (SSRIs/SNRIs), discontinuation symptoms may occur in the newborns if venlafaxine is used until or shortly before birth. Some newborns exposed to venlafaxine late in the third trimester have developed complications requiring tube-feeding, respiratory support or prolonged hospitalisation. Such complications can arise immediately upon delivery.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated an association of PPHN to SNRI treatment, this potential risk cannot be ruled out with venlafaxine taking into account the related mechanism of action (inhibition of the re-uptake of serotonin).</p><p>The following symptoms may be observed in neonates if the mother has used an SSRI/SNRI late in pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping. These symptoms may be due to either serotonergic effects or exposure symptoms. In the majority of cases, these complications are observed immediately or within 24 hours after partus.</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI/SNRI exposure within the month prior to birth (see sections 4.4, 4.8).</p><p><u>Breastfeeding</u></p><p>Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. There have been postmarketing reports of breast-fed infants who experienced crying, irritability, and abnormal sleep patterns. Symptoms consistent with venlafaxine drug discontinuation have also been reported after stopping breast-feeding. A risk to the suckling child cannot be excluded. Therefore, a decision to continue/discontinue breast-feeding or to continue/discontinue therapy with venlafaxine should be made, taking into account the benefit of breast-feeding to the child and the benefit of venlafaxine therapy to the woman.</p><p><u>Fertility</u></p><p>Reduced fertility was observed in a study in which both male and female rats were exposed to O-desmethylvenlafaxine. The human relevance of this finding is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any psychoactive medicinal product may impair judgment, thinking, and motor skills. Therefore, any patient receiving venlafaxine should be cautioned about their ability to drive or operate hazardous machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Adverse reactions reported as very common (&gt;1/10) in clinical studies were nausea, dry mouth, headache and sweating (including night sweats).</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed below by system organ class, frequency category and decreasing order of medical seriousness within each frequency category.</p><p>Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Agranulocytosis*, Aplastic anaemia*, Pancytopaenia*, Neutropaenia*</p></td><td style="vertical-align:top"><p>Thrombocytopaenia*</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reaction*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion*</p></td><td style="vertical-align:top"><p>Blood prolactin increased*</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyponatraemia*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Confusional state*, Depersonalization*, Abnormal dreams, Nervousness, Libido decreased, Agitation*, Anorgasmia</p></td><td style="vertical-align:top"><p>Mania, Hypomania, Hallucination, Derealisation, Abnormal orgasm, Bruxism*, Apathy,</p></td><td style="vertical-align:top"><p>Delirium*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Suicidal ideation and suicidal behaviours<sup>a</sup>, Aggression<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache*<sup>c</sup>, Dizziness, Sedation</p></td><td style="vertical-align:top"><p>Akathisia*, Tremor, Paraesthesia, Dysgeusia</p></td><td style="vertical-align:top"><p>Syncope, Myoclonus, Balance disorder*, Coordination abnormal*, Dyskinaesia*</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome (NMS)*, Serotonin syndrome*, Convulsion, Dystonia*</p></td><td style="vertical-align:top"><p>Tardive dyskinaesia*</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Visual impairment, Accommodation disorder, including vision blurred, Mydriasis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Angle-closure glaucoma*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia, Palpitations*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Torsade de pointes*, Ventricular tachycardia*, Ventricular fibrillation, Electrocardiogram QT prolonged*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypertension, Hot flush</p></td><td style="vertical-align:top"><p>Orthostatic hypotension, Hypotension*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspnoea*, Yawning</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Interstitial lung disease*, Pulmonary eosinophilia*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, Dry mouth, Constipation</p></td><td style="vertical-align:top"><p>Diarrhoea*, Vomiting</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage*</p></td><td style="vertical-align:top"><p>Pancreatitis*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal*</p></td><td style="vertical-align:top"><p>Hepatitis*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Hyperhidrosis* (including night sweats) *</p></td><td style="vertical-align:top"><p>Rash, Pruritus*</p></td><td style="vertical-align:top"><p>Urticaria*, Alopecia*, Ecchymosis, Angioedema*, Photosensitivity reaction</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome*, Toxic epidermal necrolysis*, Erythema multiforme*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhabdomyolysis*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Urinary hesitation, Urinary retention,Pollakiuria *</p></td><td style="vertical-align:top"><p>Urinary incontinence</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Menorrhagia*, Metrorrhagia*, Erectile dysfunction, Ejaculation disorder,</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Postpartum haemorrhaged*<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fatigue, Asthenia, Chills*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mucosal haemorrhage*</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Weight decreased, Weight increased , Blood cholesterol increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bleeding time prolonged*</p></td><td>&nbsp;</td></tr></tbody></table><p>*ADR identified postmarketing</p><p>a Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see section 4.4).</p><p>b See section 4.4</p><p>c In pooled clinical trials, the incidence of headache with venlafaxine and placebo were similar.</p><p>d This event has been reported for the therapeutic class of SSRIs/SNRIs.</p><p><u>Discontinuation of treatment</u></p><p>Discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, vertigo, headache, flu syndrome, visual impairment and hypertension are the most commonly reported reactions. Generally, these events are mild to moderate and are self limiting; however, in some patients, they may be severe and/or prolonged. It is therefore advised that when venlafaxine treatment is no longer required, gradual discontinuation by dose tapering should be carried out. However, in some patients severe aggression, and suicidal ideation occurred when the dose was reduced or during discontinuation (see sections 4.2 and 4.4).</p><p><u>Paediatric population</u></p><p>In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children and adolescents (ages 6 to 17) was similar to that seen for adults. As with adults, decreased appetite, weight loss, increased blood pressure, and increased serum cholesterol were observed (see section 4.4).</p><p>In paediatric clinical trials the adverse reaction suicidal ideation was observed. There were also increased reports of hostility and, especially in major depressive disorder, self-harm.</p><p>Particularly, the following adverse reactions were observed in paediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + 966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>e-mail:<u> npc.drug@sfda.gov.sa</u></p><p>Website: <u>https://ade.sfda.gov.sa</u></p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In postmarketing experience, overdose with venlafaxine was reported predominantly in combination with alcohol and/or other medicinal products. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, convulsion, and vomiting. Other reported events include electrocardiographic changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation [see section 5.1]), ventricular tachycardia, bradycardia, hypotension, vertigo, and deaths.</p><p>Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher burden of suicide risk factors than SSRI patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristics of venlafaxine-treated patients, is not clear. Prescriptions for venlafaxine should be written for the smallest quantity of the medicinal product consistent with good patient management in order to reduce the risk of overdose.</p><p><u>Recommended treatment</u></p><p>General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must be monitored. When there is a risk of aspiration, induction of emesis is not recommended. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of activated charcoal may also limit absorption of the active substance. Forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antidepressants - ATC code: NO6A X16.</p><p><strong>Mechanism of action</strong></p><p>The mechanism of venlafaxine&#39;s antidepressant action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system. Preclinical studies have shown that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin and norepinephrine reuptake. Venlafaxine also weakly inhibits dopamine uptake. Venlafaxine and its active metabolite reduce &beta;-adrenergic responsiveness after both acute (single dose) and chronic administration. Venlafaxine and ODV are very similar with respect to their overall action on neurotransmitter reuptake and receptor binding.</p><p>Venlafaxine has virtually no affinity for rat brain muscarinic, cholinergic, H<sub>1</sub>-histaminergic or &alpha;<sub>1</sub>-adrenergic receptors <em>in vitro</em>. Pharmacological activity at these receptors may be related to various side effects seen with other antidepressant medicinal products, such as anticholinergic, sedative and cardiovascular side effects.</p><p>Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.</p><p><em>In vitro</em> studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine sensitive receptors.</p><p><strong>Clinical efficacy and safety</strong></p><p><u>Major depressive episodes</u></p><p>The efficacy of venlafaxine immediate-release as a treatment for major depressive episodes was demonstrated in five randomised, double-blind, placebo-controlled, short-term trials ranging from 4 to 6 weeks duration, for doses up to 375 mg/day. The efficacy of venlafaxine prolonged-release as a treatment for major depressive episodes was established in two placebo-controlled, short-term studies for 8 and 12 weeks duration, which included a dose range of 75 to 225&nbsp;mg/day.</p><p>In one longer-term study, adult outpatients who had responded during an 8-week open trial on venlafaxine prolonged-release (75, 150, or 225 mg) were randomised to continuation of their same venlafaxine prolonged-release dose or to placebo, for up to 26 weeks of observation for relapse.</p><p>In a second longer-term study, the efficacy of venlafaxine in prevention of recurrent depressive episodes for a 12-month period was established in a placebo-controlled double-blind clinical trial in adult outpatients with recurrent major depressive episodes who had responded to venlafaxine treatment (100 to 200 mg/day, on a twice daily schedule) on the last episode of depression.</p><p><u>Generalised anxiety disorder</u></p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for generalised anxiety disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 to 225&nbsp;mg/day), one 6-month, placebo-controlled, fixed-dose study (75 to 225 mg/day), and one 6-month, placebo-controlled, flexible-dose study (37.5, 75, and 150 mg/day) in adult outpatients.</p><p>While there was also evidence for superiority over placebo for the 37.5 mg/day dose, this dose was not as consistently effective as the higher doses.</p><p><u>Social anxiety disorder</u></p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for social anxiety disorder was established in four double-blind, parallel-group, 12-week, multi-center, placebo-controlled, flexible-dose studies and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose study in adult outpatients. Patients received doses in a range of 75 to 225&nbsp;mg/day. There was no evidence for any greater effectiveness of the 150 to 225 mg/day group compared to the 75 mg/day group in the 6-month study.</p><p><u>Panic disorder</u></p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for panic disorder was established in two double-blind, 12-week, multi-center, placebo-controlled studies in adult outpatients with panic disorder, with or without agoraphobia. The initial dose in panic disorder studies was 37.5 mg/day for 7 days. Patients then received fixed doses of 75 or 150 mg/day in one study and 75 or 225 mg/day in the other study.</p><p>Efficacy was also established in one long-term double-blind, placebo-controlled, parallel-group study of the long-term safety, efficacy, and prevention of relapse in adult outpatients who responded to open-label treatment. Patients continued to receive the same dose of venlafaxine prolonged-release that they had taken at the end of the open-label phase (75, 150, or 225 mg).</p><p><u>Cardiac electrophysiology</u></p><p>In a dedicated thorough QTc study in healthy subjects, venlafaxine did not prolong the QT interval to any clinically relevant extent at a supra-therapeutic dose of 450 mg/day (given as 225&nbsp;mg twice daily). However, post marketing cases of QTc prolongation/TdP and ventricular arrhythmia have been reported, especially in overdose or in patients with other risk factors for QTc prolongation/TdP (see sections 4.4, 4.8 and 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine (ODV). Mean &plusmn; SD plasma half-lives of venlafaxine and ODV are 5&plusmn;2 hours and 11&plusmn;2 hours, respectively. Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral multiple-dose therapy. Venlafaxine and ODV exhibit linear kinetics over the dose range of 75 mg to 450 mg/day.</p><p><u>Absorption</u></p><p>At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine. Absolute bioavailability is 40% to 45% due to presystemic metabolism. After immediate-release venlafaxine administration, the peak plasma concentrations of venlafaxine and ODV occur in 2 and 3 hours, respectively. Following the administration of venlafaxine prolonged-release capsules, peak plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours, respectively. When equal daily doses of venlafaxine are administered as either an immediate-release tablet or prolonged-release capsule, the prolonged-release capsule provides a slower rate of absorption, but the same extent of absorption compared with the immediate-release tablet. Food does not affect the bioavailability of venlafaxine and ODV.</p><p><u>Distribution</u></p><p>Venlafaxine and ODV are minimally bound at therapeutic concentrations to human plasma proteins (27% and 30%, respectively). The volume of distribution for venlafaxine at steady-state is 4.4 &plusmn; 1.6 L/kg following intravenous administration.</p><p><u>Biotransformation</u></p><p>Venlafaxine undergoes extensive hepatic metabolism.&nbsp;<em>In vitro</em>&nbsp;and in vivo studies indicate that venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6.&nbsp;<em>In vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies indicate that venlafaxine is metabolised to a minor, less active metabolite, N-desmethylvenlafaxine, by CYP3A4.&nbsp;<em>In vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies indicate that venlafaxine is a weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2, CYP2C9, or CYP3A4.</p><p><u>Elimination</u></p><p>Venlafaxine and its metabolites are excreted primarily through the kidneys. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Mean &plusmn; SD plasma steady-state clearances of venlafaxine and ODV are 1.3&plusmn;0.6 L/h/kg and 0.4&plusmn;0.2 L/h/kg, respectively.</p><p><u>Special populations</u></p><p><em>Age and gender</em></p><p>Subject age and gender do not significantly affect the pharmacokinetics of venlafaxine and ODV.</p><p><em>CYP2D6 extensive/poor metabolisers</em></p><p>Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive metabolisers. Because the total exposure (AUC) of venlafaxine and ODV is similar in poor and extensive metabolisers, there is no need for different venlafaxine dosing regimens for these two groups.</p><p><em>Hepatic impairment</em></p><p>In Child-Pugh A (mildly hepatically impaired) and Child-Pugh B (moderately hepatically impaired) subjects, venlafaxine and ODV half-lives were prolonged compared to normal subjects. The oral clearance of both venlafaxine and ODV was reduced. A large degree of intersubject variability was noted. There are limited data in patients with severe hepatic impairment (see section 4.2).</p><p><em>Renal impairment</em></p><p>In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance reduced by about 57% compared to normal subjects, while ODV elimination half-life was prolonged by about 142% and clearance reduced by about 56%. Dosage adjustment is necessary in patients with severe renal impairment and in patients that require haemodialysis (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies with venlafaxine in rats and mice revealed no evidence of carcinogenesis. Venlafaxine was not mutagenic in a wide range of <em>in vitro</em> and <em>in vivo</em> tests.</p><p>Animal studies regarding reproductive toxicity have found in rats a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation. The cause of these deaths is unknown. These effects occurred at 30 mg/kg/day, 4 times the human daily dose of 375 mg of venlafaxine (on an mg/kg basis). The no-effect dose for these findings was 1.3 times the human dose. The potential risk for humans is unknown.</p><p>Reduced fertility was observed in a study in which both male and female rats were exposed to ODV. This exposure was approximately 1 to 2 times that of a human venlafaxine dose of 375&nbsp;mg/day. The human relevance of this finding is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content:</u></p><p><em>Tablet core:</em></p><p>-&nbsp;&nbsp; Hypromellose</p><p>-&nbsp;&nbsp; Eudragit</p><p>-&nbsp;&nbsp; Sodium lauryl sulfate</p><p>-&nbsp;&nbsp; Magnesium stearate</p><p><em>Tablet coat:</em></p><p>-&nbsp;&nbsp; Eudragit</p><p><u>Capsule shell:</u></p><p>-&nbsp;&nbsp; Titanium dioxide</p><p>-&nbsp;&nbsp; Gelatin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opaque white PVC/PE/PVDC/aluminum blisters.</p><p>Pack size: 14 Prolonged-release hard capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 January 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>